GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise for rare, severe psoriasis flares
Disease control OngoingThis study tests an oral medication, JNJ-77242113, in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The goal is to see if the drug can control symptoms like widespread redness, pustules, and swelling.…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated May 26, 2026 07:08 UTC
-
New drug shows promise for rare, severe psoriasis
Disease control OngoingThis study tests whether TAK-279 can improve symptoms of two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. All 18 adult participants will receive TAK-279 for up to 52 weeks. The main goal is to see how many achieve clear or almost…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 07:08 UTC
-
New hope for rare skin disease: 5-Year drug trial shows promise
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug spesolimab for people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study. They will receive the drug for up to 5 …
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 07:04 UTC
-
New hope for rare skin disease: drug targets repeated flares
Disease control OngoingThis study tests whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare before receive an infusion of spesolimab at the start of a new flare, with a possi…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE4 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 07:03 UTC
-
Study on spesolimab for severe psoriasis flares withdrawn before starting
Disease control TerminatedThis study was designed to track the safety and effectiveness of spesolimab in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The plan was to observe patients receiving the drug in routine medical practice, focusing on side eff…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 04:38 UTC